The LDN Shop
Visit our e-commerce website for Conferences, Webinars, Medical Membership, eBooks etc
LDN Social Media
Get connected with us on social networks
Low dose naltrexone in refractory neuropathic pain associated with autoimmune transverse myelitis
J Pain
01 April 2015
https://www.jpain.org/article/S1526-5900(15)00354-5/fulltext
A case of transverse myelitis (TM) with secondary central pain syndrome refractory to multiple pain medications and immune-modulation therapies, which responded to low dose (3-4.5 mg) Naltrexone.
Endogenous opioid inhibition of proliferation of T and B cell subpopulations in response to immunization for experimental autoimmune encephalomyelitis
BMC Immunol
24 April 2015
https://pubmed.ncbi.nlm.nih.gov/25906771/
Dickson Chemist developed a new formulation of LDN which will hopefully improve the outcomes for patients. This new formulation is a more concentrated liquid in the form of drops which are administered under the tongue and absorbed directly from the mucosal lining of the mouth. This sublingual route produces a more rapid absorption bypassing the liver and digestive tract. There are several potential advantages to this, the drug may be more effective and will not be affected by the presence of food stuffs or the hostile environment of the gut.